References
- Asan Medical Center. Disease information - osteoporosis. Available from http://www.amc.seoul.kr/asan/healthinfo/disease/diseaseDetail.do?contentId=31611. Accessed January 20, 2021.
- Lee JS, Jang SO. A study on reference values and prevalence of osteoporosis in Korea: the Korea national health and nutrition examination survey 2008-2011. J Korean Off Stat 2013;18(2):42-65.
- Healthcare Bigdata Hub. Statistics of national disease - osteoporosis. Available from http://opendata.hira.or.kr/op/opc/olapMfrnIntrsIlnsInfo.do. Accessed January 20, 2021.
- Chun SW. Pharmacological treatment of osteoporosis. J Korean Med Assoc 2019;62(10):542-50. https://doi.org/10.5124/jkma.2019.62.10.542
- Ganesan K, Bansal P, Goyal A, Roane D. Bisphosphonate. Available from https://www.ncbi.nlm.nih.gov/books/NBK470248/#article18343.s9. Accessed February 08, 2020.
- Choi HJ. Treatment for osteoporosis: focusing for bisphosphonate therapy. Korean J Fam Pract 2013;3(1):16-24.
- Wysowski DK, Chang JT. Alendronate and risedronate: reports of severe bone, joint, and muscle pain. Arch Intern Med 2005;165(3):346-7. https://doi.org/10.1001/archinte.165.3.350
- FDA alert. Severe musculoskeletal pain a risk with bisphosphonates. Available from https://www.healio.com/endocrinology/bone-mineralmetabolism/news/print/endocrine-today/%7Bfafc5981-b3e5-4307-9ad8-2a192a433bbd%7D/fda-alert-severe-musculoskeletal-pain-arisk-with-bisphosphonates. Accessed November 5, 2019.
- Thiebaud D, Sauty A, Burckhardt P, et al. An in vitro and in vivo study of cytokines in the acute-phase response associated with bisphosphonates. Calcif Tissue Int 1997;61(1):386-92. https://doi.org/10.1007/s002239900353
- Ugurlar M. Alendronate- and risedronate-induced acute polyarthritis. Osteoporos Int 2016;27(1):3383-5. https://doi.org/10.1007/s00198-016-3695-3
- Kang MK, Yoon NK. A study of adverse drug event reporting systems in Korea. Korean J Community Pharm. 2019;5(1):56-65.
- Patient Safety Drug Management Division, Korean Pharmaceutical Association. Regional drug safety center information. Available from https://www.safepharm.or.kr/sub_2_1.do. Accessed May 10, 2021.
- Korea Institute of Drug Safety and Risk Management. Regional drug safety center information and history. Available from https://www.drugsafe.or.kr/iwt/ds/ko/community/EgovCenterGuide.do Accessed January 20, 2021.
- Jin XM, Kim YJ, Yang BR, Choi NK, Park BJ. The role of consumers in the spontaneous adverse drug events reporting. J Pharmacoepidemiol Risk Manag 2010;3(3):101-12.
- Kang DY. The active pharmacovigilance system: a postscript of visiting the harvard pilgrim health care institute. J Pharmacoepidemiol Risk Manag 2017;9:45-7.
- Gordis L. Epidemiology, 5th Ed. Philadelphia: Elsevier, 2014: 198-199.
- Mor A, H.Pillinger M, L.Wortmann R, J.Mitnick H. Drug-induced arthritic and connective tissue disorders. Semin Arthritis Rheum 2008;38(3):249-64. https://doi.org/10.1016/j.semarthrit.2007.10.001
- Adwan MH. An update on drug-induced arthritis. Rheumatology International. 2016;36(1):1089-97. https://doi.org/10.1007/s00296-016-3462-y
- Bannwarth B. Drug-Induced Musculoskeletal Disorders. Drug Saf 2007;30(1):27-46. https://doi.org/10.2165/00002018-200730010-00004
- Lewiecki EM. Bisphosphonates for the treatment of osteoporosis: insights for clinicians. Ther Adv Chronic Dis 2010;1(3):115-28. https://doi.org/10.1177/2040622310374783
- Lee J, Lee EH, Jung JW, Kang HR, Cho SH. Public awareness of adverse drug reactions and pharmacovigilance system in Korea. J Pharmacoepidemiol Risk Manag 2012;5(2):68-77.
- Korean Medical Library Engine. Alendronate. Available from http://www.kmle.co.kr. Accessed February 26, 2021.
- Ministry of Food and Drug Safety. Change order for drug permission (bisphosphonate). Available from https://nedrug.mfds.go.kr/bbs/58/2182/. Accessed February 08, 2021.
- Bock O, Boerst H, Thomasius FE, et al. Common musculoskeletal adverse effects of oral treatment with once weekly alendronate and risedronate in patients with osteoporosis and ways for their prevention. J Musculoskelet Neuronal Interact 2007;7(2):144-8.
- Kim JA, Yoon S, Kim LY, Kim DS. Towards Actualizing the Value Potential of Korea Health Insurance Review and Assessment (HIRA) Data as a Resource for Health Research: Strengths, Limitations, Applications, and Strategies for Optimal Use of HIRA Data. J Korean Med Sci 2017;32(5):718-728. https://doi.org/10.3346/jkms.2017.32.5.718
- Kim SH, Kim H. Pictogram design for the assessment of pediatric pain. Journal of Integrated Design Research 2019;18(4):115-29.
- Hazell L, Shakir SAW. Under-reporting of adverse drug reactions. Drug Saf 2006;29(5):385-96. https://doi.org/10.2165/00002018-200629050-00003
- Rothman ML, Beltran P, Cappelleri JC, Lipscomb J, Teschendorf B. Patient-reported outcomes: conceptual issues. Value Health 2007;10(Suppl 2):S66-75. https://doi.org/10.1111/j.1524-4733.2007.00269.x
- Schmier JK, Halpern MT. Patient recall and recall bias of health state and health status. Expert Rev Pharmacoecon Outcomes Res 2004;4(2):159-63. https://doi.org/10.1586/14737167.4.2.159